{"SPADE_N_14667": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14667", "Peptide Name": "NZX (D9S, M13I, and K32R plectasin analog, synthetic AMPs, 3S=S, UCSS1a)", "Source": "amino acid substitution, fungal defensin analog, fungi-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCARGGFVCKCY", "Sequence Length": 40, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-MRSA"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 4389.93, "PI": 8.3, "Hydrophobicity": -0.58, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Liu H, Yang N, Mao R, Teng D, Hao Y, Wang X, Wang J.2020", "Reference": "Appl Microbiol Biotechnol. 2020 Feb;104(4):1555-1568. doi: 10.1007/s00253-019-10313-3.PubMed", "Title": "A new high-yielding antimicrobial peptide NZX and its antibacterial activity against Staphylococcus hyicus in vitro/vivo."}], "Frequent Amino Acids": "GCK", "Absent Amino Acids": "LMOTU", "Basic Residues": 7, "Acidic Residues": 3, "Hydrophobic Residues": 11, "Polar Residues": 23, "Positive Residues": 7, "Negative Residues": 3, "Net Charge": 4, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (97.5%) toNZL (NZ2114 variant 6)G: 20%; C: 15%.  Four K residues were replaced with four R.Activity:  Active against S. aureus ATCC43300 MRSA or TCC25923 (MIC 0.46-0.91 uM) and S. hyicus NCTC10350 or 437â€“2 (MIC 0.91 uM).Peptide stability:  not heat stable at 100oC after 1 h incubation (ok till 80oC). pepsin-resistant but trypsin-sensitive.Antimicrobial robustness: activity is pH-insensitive (pH 2-10).In vitro toxicity: mouse RBC: 1.9% hemolysis at 128 ug/ml (poor hemo.lytic). No cytotoxicity to HaCaT cell (92.7% survival at 128 ug/ml).Animal model:mouse: peritonitis model, female ICR mice infected with S. hyicus NCTC10350, i.p./i.p., mice survived 67% and 100% treated twice at 5 and 10 mg/kg, respectively.In vivo PK:mice:IV: t1/2 0.32-0.45 h Cmax 2.85-20.55 ug/ml (Zheng et al., 2022).Recombinant production:yeast:Pichia pastoris X33: expressed and ion exchange purified, yield: 965 mg/L; purity: 92.6% based on 5 L fermenetor.", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_22184", "Similarity": 1.0, "Sequence": "GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCARGGFVCKCY"}, {"SPADE_ID": "SPADE_N_14125", "Similarity": 0.975, "Sequence": "GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCAKGGFVCKCY"}, {"SPADE_ID": "SPADE_N_14126", "Similarity": 0.975, "Sequence": "GFGCNGPWSEDDLQCHNHCKSIKGYKGGYCARGGFVCKCY"}]}}}